Aduro BioTech Secures $19,250,000 Series B Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3763e8dd-0a7b-445d-b5ae-bf25bf93d29b&Preview=1 -
Date
4/20/2011 -
Company Name
Aduro BioTech -
Mailing Address
626 Bancroft Way Berkeley, CA 94710 -
Company Description
Aduro BioTech is a clinical-stage immunotherapy company with a platform technology for therapeutic and prophylactic vaccines for cancer and infectious diseases. The platform of attenuated and targeted vaccines based on Listeria monocytogenes has been in development for nine years. -
Website
http://www.adurobiotech.com -
Transaction Type
Venture Equity -
Transaction Amount
$19,250,000 -
Transaction Round
Series B -
Proceeds Purposes
This new round of funding enables us to advance our lead cancer vaccine, CRS-207, into a Phase 2 clinical trial in pancreatic cancer. In addition, these funds will support initial clinical development of CRS-207 for other indications and preclinical development of therapeutic vaccines for prostate cancer and melanoma as well as prophylactic vaccines for malaria and tularemia. -
M&A Terms
-
Venture Investor
Morningside Group -
Venture Investor
Undisclosed
